Investigating the effect of magnesium hydroxide on improving ileus after abdominal surgeries; Clinical trial study

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20130612013656N2

Enrollment

260

Registered

2026-04-21

Start date

2026-05-20

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ileus recovery. Paralytic ileus

Interventions

Intervention 1: Intervention group: Receiving magnesium hydroxide syrup (MOM) from Alborz Darou Company, Laxy Gel brand, made in Iran, immediately after the operation, 30 cc every 8 hours, with an eff

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Patients undergoing elective abdominal surgery with a midline incision who received bowel prep. Patients aged between 18-75

Exclusion criteria

Exclusion criteria: Critically ill patients with neuromuscular problems who are unable to move Patients who are unconscious, uncommunicative, or mentally retarded Unwillingness to undergo the intervention Contraindications for the use of magnesium hydroxide (kidney failure, sensitivity to magnesium hydroxide, heart block, cardiac arrhythmias, etc.)

Design outcomes

Primary

Measure	Time frame
Passing gas or stool. Timepoint: At 12, 24, 36, and 48 hours after surgery. Method of measurement: Post-surgery questionnaire.	—

Secondary

Measure	Time frame
Nausea. Timepoint: At 12, 24, 36, and 48 hours after surgery. Method of measurement: Post-surgery questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSeyed Muhammad Mehdi Ghaffari Hamedani

Mazandaran University of Medical Sciences

ghaffari99@yahoo.com+98 11 3336 1700

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Jun 11, 2026